Citations (47)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Bernard Escudier, Francis Worden & Masatoshi Kudo. (2019) Sorafenib: key lessons from over 10 years of experience. Expert Review of Anticancer Therapy 19:2, pages 177-189.
Read now
Read now
Articles from other publishers (46)
Lamya H. Al-Wahaibi, Anber F. Mohammed, Mostafa H. Abdelrahman, Laurent Trembleau & Bahaa G. M. Youssif. (2023) Design, Synthesis, and Biological Evaluation of Indole-2-carboxamides as Potential Multi-Target Antiproliferative Agents. Pharmaceuticals 16:7, pages 1039.
Crossref
Crossref
Alanoud Altalal, Aliyah Almomen, Musaed Alkholief, Ziyad Binkhathlan, Nourah Z. Alzoman & Aws Alshamsan. (2023) Development and validation of a UPLC-MS/MS method for simultaneous detection of doxorubicin and sorafenib in plasma: Application to pharmacokinetic studies in rats. Saudi Pharmaceutical Journal 31:7, pages 1317-1326.
Crossref
Crossref
Klaudia Katarzyna Brogowska, Monika Zajkowska & Barbara Mroczko. (2023) Vascular Endothelial Growth Factor Ligands and Receptors in Breast Cancer. Journal of Clinical Medicine 12:6, pages 2412.
Crossref
Crossref
Amr Elagamy, Laila K. Elghoneimy & Reem K. Arafa. 2023. Recent Developments in the Synthesis and Applications of Pyridines. Recent Developments in the Synthesis and Applications of Pyridines
375
410
.
Jiayi Li, Xin Zhang, Zhuanzhuan Mu, Di Sun, Yuqing Sun & Yansong Lin. (2022) Response to apatinib and camrelizumab combined treatment in a radioiodine refractory differentiated thyroid cancer patient resistant to prior anti-angiogenic therapy: A case report and literature review. Frontiers in Immunology 13.
Crossref
Crossref
Xiaolian Li, Mingkun Xu, Jiaojiao Shen, Yuqin Li, Shaoping Lin, Min Zhu, Qiongni Pang, Xiujuan Tan & Jing Tang. (2022) Sorafenib inhibits LPS-induced inflammation by regulating Lyn-MAPK-NF-kB/AP-1 pathway and TLR4 expression. Cell Death Discovery 8:1.
Crossref
Crossref
Mototsugu Oya, Shuichi Kaneko, Tsuneo Imai, Toshiaki Tsujino, Toshiyuki Sunaya & Yutaka Okayama. (2022) RETRACTED ARTICLE: Effectiveness and safety of sorafenib for renal cell, hepatocellular and thyroid carcinoma: pooled analysis in patients with renal impairment. Cancer Chemotherapy and Pharmacology 89:6, pages 761-772.
Crossref
Crossref
Marianna Caterino, Mario Pirozzi, Sergio Facchini, Alessia Zotta, Antonello Sica, Giorgio Lo Giudice, Raffaele Rauso, Elisa Varriale, Fortunato Ciardiello & Morena Fasano. (2022) Sorafenib in Metastatic Papillary Thyroid Carcinoma with BRAF K601E Mutation on Liquid Biopsy: A Case Report and Literature Review. Medicina 58:5, pages 666.
Crossref
Crossref
Francesca Laneri, Adriana C. E. Graziano, Mimimorena Seggio, Aurore Fraix, Milo Malanga, Szabolcs Béni, Giuseppe Longobardi, Claudia Conte, Fabiana Quaglia & Salvatore Sortino. (2022) Enhancing the Anticancer Activity of Sorafenib through Its Combination with a Nitric Oxide Photodelivering β-Cyclodextrin Polymer. Molecules 27:6, pages 1918.
Crossref
Crossref
JAIRO GOMES DA SILVA, IZABEL CRISTINA RODRIGUES DA SILVA, MOSTAFA ADIMY & PAULO FERNANDO DE ARRUDA MANCERA. (2022) THE EFFECT OF LENVATINIB AND PEMBROLIZUMAB ON THYROID CANCER REFRACTORY TO IODINE 131I SIMULATED BY MATHEMATICAL MODELING. Journal of Biological Systems 30:01, pages 93-112.
Crossref
Crossref
Nehad M. Ayoub, Sara K. Jaradat, Kamal M. Al-Shami & Amer E. Alkhalifa. (2022) Targeting Angiogenesis in Breast Cancer: Current Evidence and Future Perspectives of Novel Anti-Angiogenic Approaches. Frontiers in Pharmacology 13.
Crossref
Crossref
Osama M. Soltan, Mai E. Shoman, Salah A. Abdel-Aziz, Atsushi Narumi, Hiroyuki Konno & Mohamed Abdel-Aziz. (2021) Molecular hybrids: A five-year survey on structures of multiple targeted hybrids of protein kinase inhibitors for cancer therapy. European Journal of Medicinal Chemistry 225, pages 113768.
Crossref
Crossref
Andrée Boucher, Shereen Ezzat, Sebastien Hotte, Irina Rachinsky, Murali Rajaraman, Dean Ruether, Sam M. Wiseman, James Brierley, Cheryl Ho, Monika Krzyzanowska, Nathan Lamond, Marie-Hélène Massicotte, Shereen Joseph, Kassey Herscovitch, Lindsey Sikora & Eric Winquist. (2021) Canadian consensus statement on the management of radioactive iodine–resistant differentiated thyroid cancer. Oral Oncology 121, pages 105477.
Crossref
Crossref
Tanner Fullmer, Maria E. Cabanillas & Mark Zafereo. (2021) Novel Therapeutics in Radioactive Iodine-Resistant Thyroid Cancer. Frontiers in Endocrinology 12.
Crossref
Crossref
Vincenzo Marotta, Maria Grazia Chiofalo, Francesca Di Gennaro, Antonio Daponte, Fabio Sandomenico, Paolo Vallone, Luciana Costigliola, Gerardo Botti, Franco Ionna & Luciano Pezzullo. (2021) Kinase-inhibitors for iodine-refractory differentiated thyroid cancer: still far from a structured therapeutic algorithm. Critical Reviews in Oncology/Hematology 162, pages 103353.
Crossref
Crossref
Ting Sun, Wenhao Mao, Hui Peng, Qi Wang & Lin Jiao. (2021) YAP promotes sorafenib resistance in hepatocellular carcinoma by upregulating survivin. Cellular Oncology 44:3, pages 689-699.
Crossref
Crossref
Matti L. Gild, Venessa H. M. Tsang, Roderick J. Clifton-Bligh & Bruce G. Robinson. (2021) Multikinase inhibitors in thyroid cancer: timing of targeted therapy. Nature Reviews Endocrinology 17:4, pages 225-234.
Crossref
Crossref
Nicola d'Avanzo, Giulia Torrieri, Patrícia Figueiredo, Christian Celia, Donatella Paolino, Alexandra Correia, Karina Moslova, Tambet Teesalu, Massimo Fresta & Hélder A. Santos. (2021) LinTT1 peptide-functionalized liposomes for targeted breast cancer therapy. International Journal of Pharmaceutics 597, pages 120346.
Crossref
Crossref
Hyeok Jun Yun, Hee Jun Kim, Jungmin Kim, Sang Yong Kim, Hang-Seok Chang, Cheong Soo Park, Ho-Jin Chang & Ki Cheong Park. (2021) Synergistic Anticancer Activity of N-Hydroxy-7-(2-Naphthylthio) Heptanomide, Sorafenib, and Radiation Therapy in Patient-Derived Anaplastic Thyroid Cancer Models. International Journal of Molecular Sciences 22:2, pages 536.
Crossref
Crossref
Sadegh Rajabi, Heewa Shakib, Romina Dastmalchi, Afsoon Danesh-Afrooz, Saeed Karima & Mehdi Hedayati. (2020) Metastatic propagation of thyroid cancer; organ tropism and major modulators. Future Oncology 16:18, pages 1301-1319.
Crossref
Crossref
Abdullah F. AlAsmari, Nemat Ali, Fawaz AlAsmari, Wael A. AlAnazi, Faleh Alqahtani, Metab Alharbi, Farraj M. Alotaibi, Abdullah A. Aldossari, Mohammed AlSwayyed, Mohammed M. Alanazi & Ali A. Alshamrani. (2020) Elucidation of the Molecular Mechanisms Underlying Sorafenib-Induced Hepatotoxicity. Oxidative Medicine and Cellular Longevity 2020, pages 1-10.
Crossref
Crossref
Xieyi Zhang, Tetsuya Higuchi, Hiroyasu Tomonaga, Oyunbold Lamid-Ochir, Anu Bhattarai, Huong Nguyen-Thu, Ayako Taketomi-Takahashi, Hiromi Hirasawa & Yoshito Tsushima. (2020) Early detection of progressive disease using thyroglobulin doubling-time in metastatic differentiated thyroid carcinoma treated with radioactive iodine. Nuclear Medicine Communications 41:4, pages 350-355.
Crossref
Crossref
P. Johnsirani, Aabid Abdullah Wani, Prasad V Bharatam & Satheeshkumar Nanjappan. (2020) LC-ESI-QTOF-MS analysis utilizing gas-phase fragmentation reactions subjected to ESI-IS-CID and ESI-CID-MS/MS conditions to study the degradation behaviour of sorafenib tosylate: NMR and in vitro cytotoxicity and apoptosis detection studies of hydrolytic degradation products. Journal of Pharmaceutical and Biomedical Analysis 177, pages 112881.
Crossref
Crossref
Toru Nagao. 2020. Textbook of Oral Cancer. Textbook of Oral Cancer
359
385
.
D. Samuel Metibemu, O. Adeboye Akinloye, A. Jamiu Akamo, D. Ajiboye Ojo, O. Tolulope Okeowo & I. Olaposi Omotuyi. (2019) Exploring receptor tyrosine kinases-inhibitors in Cancer treatments. Egyptian Journal of Medical Human Genetics 20:1.
Crossref
Crossref
Selina K. Wong, Quincy S.C. Chu, Jennifer L. Spratlin, Randeep Sangha, Alexander J.B. McEwan, Donald W. Morrish, Diane Arndt, Gwen Sergenson, Adriaan Cleton, Funan Huang & Michael B. Sawyer. (2019) Prolonged Response to Regorafenib in a Patient with Iodine Refractory Thyroid Cancer. Case Reports in Oncology 12:3, pages 791-795.
Crossref
Crossref
Sheng Wang, Dexi Zhou, Zhenyu Xu, Jing Song, Xueyi Qian, Xiongwen Lv & Jiajie Luan. (2019) Anti-tumor Drug Targets Analysis: Current Insight and Future Prospect. Current Drug Targets 20:11, pages 1180-1202.
Crossref
Crossref
Agnese Latorre, Agnese Maria Fioretti, Francesco Giotta & Vito Lorusso. (2019) Efficacy and safety of lenvatinib in an elderly patient with metastatic papillary thyroid carcinoma and cardiological comorbidity: a case report. Future Oncology 15:24s, pages 27-33.
Crossref
Crossref
Stanton J. Kochanek, David A. Close, Allen Xinwei Wang, Tongying Shun, Philip E. Empey, Julie L. Eiseman & Paul A. Johnston. (2019) Confirmation of Selected Synergistic Cancer Drug Combinations Identified in an HTS Campaign and Exploration of Drug Efflux Transporter Contributions to the Mode of Synergy. SLAS Discovery 24:6, pages 653-668.
Crossref
Crossref
Rong Wang, Tadaaki Yamada, Sachiko Arai, Koji Fukuda, Hirokazu Taniguchi, Azusa Tanimoto, Akihiro Nishiyama, Shinji Takeuchi, Kaname Yamashita, Koshiro Ohtsubo, Junji Matsui, Naoyoshi Onoda, Eishu Hirata, Shu Taira & Seiji Yano. (2019) Distribution and Activity of Lenvatinib in Brain Tumor Models of Human Anaplastic Thyroid Cancer Cells in Severe Combined Immune Deficient Mice. Molecular Cancer Therapeutics 18:5, pages 947-956.
Crossref
Crossref
Matthew Martin, Antja-Voy Hartley, Jiamin Jin, Mengyao Sun & Tao Lu. 2019. Adenosine Triphosphate in Health and Disease. Adenosine Triphosphate in Health and Disease.
Shikha Saini, Kiara Tulla, Ajay V. Maker, Kenneth D. Burman & Bellur S. Prabhakar. (2018) Therapeutic advances in anaplastic thyroid cancer: a current perspective. Molecular Cancer 17:1.
Crossref
Crossref
Masayuki Tori & Toshirou Shimo. (2018) Long-term efficacy of lenvatinib for recurrent papillary thyroid carcinoma after multimodal treatment and management of complications: a case report. BMC Cancer 18:1.
Crossref
Crossref
Alessandro Prete, Agnes S. Lo, Peter M. Sadow, Swati S. Bhasin, Zeus A. Antonello, Danica M. Vodopivec, Soumya Ullas, Jennifer N. Sims, John Clohessy, Ann M. Dvorak, Tracey Sciuto, Manoj Bhasin, Joanne E. Murphy-Ullrich, Jack Lawler, S. Ananth Karumanchi & Carmelo Nucera. (2018) Pericytes Elicit Resistance to Vemurafenib and Sorafenib Therapy in Thyroid Carcinoma via the TSP-1/TGFβ1 Axis. Clinical Cancer Research 24:23, pages 6078-6097.
Crossref
Crossref
A. G. GianoukakisC. E. DutcusN. BattyM. GuoM. Baig. (2018) Prolonged duration of response in lenvatinib responders with thyroid cancer (Russian translation). Head and neck tumors (HNT) 8:3, pages 53-60.
Crossref
Crossref
Katarzyna Sawa-Wejksza & Martyna Kandefer-Szerszeń. (2017) Tumor-Associated Macrophages as Target for Antitumor Therapy. Archivum Immunologiae et Therapiae Experimentalis 66:2, pages 97-111.
Crossref
Crossref
Francesca Mastropasqua, Flaviana Marzano, Alessio Valletti, Italia Aiello, Giuseppe Di Tullio, Annalisa Morgano, Sabino Liuni, Elena Ranieri, Luisa Guerrini, Giuseppe Gasparre, Elisabetta Sbisà, Graziano Pesole, Antonio Moschetta, Mariano Francesco Caratozzolo & Apollonia Tullo. (2017) TRIM8 restores p53 tumour suppressor function by blunting N-MYC activity in chemo-resistant tumours. Molecular Cancer 16:1.
Crossref
Crossref
Yukari Mizukami, Koji Sugawara, Yukimi Kira & Daisuke Tsuruta. (2017) Sorafenib stimulates human skin type mast cell degranulation and maturation. Journal of Dermatological Science 88:3, pages 308-319.
Crossref
Crossref
Arash Ordookhani, Abbas Motazedi & Kenneth D. Burman. (2017) Thrombosis in Thyroid Cancer. International Journal of Endocrinology and Metabolism 16:1.
Crossref
Crossref
Benedikt Schmidbauer, Karin Menhart, Dirk Hellwig & Jirka Grosse. (2017) Differentiated Thyroid Cancer—Treatment: State of the Art. International Journal of Molecular Sciences 18:6, pages 1292.
Crossref
Crossref
Heqing YiXuemei YeBin LongTing YeLijun ZhangFengqin YanYang YangLinfa Li. (2017) Inhibition of the AKT/mTOR Pathway Augments the Anticancer Effects of Sorafenib in Thyroid Cancer. Cancer Biotherapy and Radiopharmaceuticals 32:5, pages 176-183.
Crossref
Crossref
Angelica Schmidt, Graciela Cross & Fabián Pitoia. (2017) Metástasis a distancia en cáncer diferenciado de tiroides: diagnóstico y tratamiento. Revista Argentina de Endocrinología y Metabolismo 54:2, pages 92-100.
Crossref
Crossref
Angelica Schmidt, Laura Iglesias, Michele Klain, Fabián Pitoia & Martin J. Schlumberger. (2017) Radioactive iodine-refractory differentiated thyroid cancer: an uncommon but challenging situation. Archives of Endocrinology and Metabolism 61:1, pages 81-89.
Crossref
Crossref
Fabián Pitoia, Angelica Schmidt, Fernanda Bueno, Yamile Mocarbel, Fernando Jerkovich & Erika Abelleira. (2017) Guía práctica para el manejo de efectos adversos por inhibidores multicinasas (sorafenib y vandetanib) en pacientes con cáncer de tiroides avanzado. Revista Argentina de Endocrinología y Metabolismo 54:1, pages 8-20.
Crossref
Crossref
Menelaos Zafrakas, Panayiota Papasozomenou & Christos Emmanouilides. (2016) Sorafenib in breast cancer treatment: A systematic review and overview of clinical trials. World Journal of Clinical Oncology 7:4, pages 331.
Crossref
Crossref
Janani Kumar. 2016. STAT Inhibitors in Cancer. STAT Inhibitors in Cancer
177
190
.